Zinetac 300mg Tablet contains ranitidine, a histamine H2-receptor antagonist that effectively reduces gastric acid secretion. It is primarily indicated for the treatment and prevention of conditions associated with excessive stomach acid such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and erosive esophagitis. By selectively blocking H2 receptors on gastric parietal cells, Zinetac decreases both basal and stimulated acid secretion, promoting ulcer healing and symptom relief. The 300mg dosage is typically prescribed for more severe acid-related disorders or for maintenance therapy to prevent recurrence. Zinetac is administered orally, with or without food, and dosage adjustments may be necessary based on clinical response and renal function. Common adverse effects are generally mild and may include headache, dizziness, constipation, or diarrhea. Caution is advised in patients with hepatic impairment or those taking concomitant medications metabolized via cytochrome P450 enzymes due to potential drug interactions. Zinetac should be used under medical supervision, and patients should report any unusual symptoms such as allergic reactions or persistent gastrointestinal discomfort. Regular monitoring may be warranted during prolonged therapy to ensure efficacy and safety.